Abstract
As the impact of dengue expands, a safe and effective vaccine will benefit the world greatly. Recent progress and novel approaches have advanced the field, but many challenges and unanswered questions remain for dengue vaccine developers. The most advanced dengue vaccine candidate, a chimeric yellow fever dengue (CYD) tetravalent vaccine, was the first dengue vaccine tested in a field efficacy trial. Several live-attenuated and inactivated vaccine candidate utilizing different antigen-presenting methods and adjuvants are currently in clinical trials. This manuscript highlights results of recent dengue vaccine studies, describes ongoing trials, and discusses future possibilities.
| Original language | English |
|---|---|
| Pages (from-to) | 6-12 |
| Number of pages | 7 |
| Journal | Current Tropical Medicine Reports |
| Volume | 1 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 1 2014 |
Keywords
- DNA dengue vaccine
- Dengue serotype
- Dengue vaccine
- Merck recombinant envelope protein dengue vaccine
- NIH-directed mutagenesis dengue vaccine
- Sanofi Pasteur chimeric yellow fever dengue vaccine
- Takeda chimeric dengue vaccine
- Viral tropical medicine
- WRAIR GSK dengue purified inactivated vaccine
Fingerprint
Dive into the research topics of '“Current Dengue Vaccine Status”'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver